Inovio Pharmaceuticals market cap INO
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $195.4M
- Highest close in our data
- $4.7B
- Jun 2020
Inovio Pharmaceuticals is worth $195.4M at the close on Nov 2, 2026, at $1.89 a share.
That is up 73% over the last year and down 86% over five years.
Its highest close in our data was $4.7B in Jun 2020.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $195.4M | $55M | $195.4M | +59% |
| 2025 | $122.7M | $48.8M | $148.3M | +151% |
| 2024 | $48.8M | $48M | $324.4M | −65% |
| 2023 | $139.2M | $95.5M | $476.5M | −64% |
| 2022 | $389.2M | $345.9M | $999.3M | −63% |
| 2021 | $1B | $1B | $2.4B | −30% |
| 2020 | $1.5B | $298M | $4.7B | +349% |
| 2019 | $334M | $208M | $486.3M | −12% |
| 2018 | $381.4M | $356.6M | $510.1M | +2% |
| 2017 | $372.9M | $372.9M | $611.9M | −27% |
| 2016 | $514M | $366M | $809.9M | +6% |
| 2015 | $485.1M | $412M | $640.5M | −14% |
| 2014 | $567.1M | $481.3M | $884.2M | −4% |
| 2013 | $589.7M | $73.9M | $589.7M | +764% |
| 2012 | $68.3M | $54M | $95.8M | +25% |
| 2011 | $54.7M | $47.1M | $91.6M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Inovio Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| INOInovio Pharmaceuticals | $195.4M |
| NATRNatures Sunshine Products | $211.5M |
| CRMDCorMedix | $420.1M |
| ARVNArvinas | $491.7M |
| LFVNLifevantage | $73.5M |
| PBYIPuma Biotechnology | $525.5M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $599.8M |
| SPROSpero Therapeutics | $60.6M |
| COLLCollegium Pharmaceutical | $770.9M |
| ABUSArbutus Biopharma | $791.4M |
| Peer median | $508.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Inovio Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.